Page last updated: 2024-12-06

furylfuramide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Furylfuramide: Used formerly as antimicrobial food additive. It causes mutations in many cell cultures and may be carcinogenic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(Z)-2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide : A member of the class of acrylamides that is acrylamide which is substituted at positions 2 and 3 by 2-furyl and 5-nitro-2-furyl groups, respectively (the trans isomer). Formerly used as a food preservative, it was withdrawn from the market following suspicions of carcenogenicity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5280707
CHEMBL ID259747
CHEBI ID15660
SCHEMBL ID106825
MeSH IDM0008905

Synonyms (47)

Synonym
CHEBI:15660 ,
(2z)-2-(2-furyl)-3-(5-nitro-2-furyl)prop-2-enamide
mls002608680 ,
nsc44973
2-furanacetamide, .alpha.-[(5-nitro-2-furanyl)methylene]-
furylfuramide
wln: t5oj byvzu1- bt5oj enw
af 2
furylamide
af-2
af 2 (preservative)
acrylamide, 2-(2-furyl)-3-(5-nitro-2-furyl)-
nsc-44973
2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide
2-furanacrylamide, .alpha.-2-furyl-5-nitro-
(2z)-2-(furan-2-yl)-3-(5-nitrofuran-2-yl)prop-2-enamide
af-2 (tn)
D02528
2-furanacrylamide, alpha-2-furyl-5-nitro-, (z)-
2-furanacetamide, alpha-((5-nitro-2-furanyl)methylene)-, (z)-
(z)-alpha-2-furyl-5-nitro-2-furanacrylamide
cis-af 2
cis-3-(5-nitro-2-furyl)-2-(2-furyl)acrylamide
cis-furylfuramide
alpha-(furyl)-beta-(5-nitro-2-furyl)acrylic amide
tofuron
alpha-((5-nitro-2-furanyl)methylene)-2-furanacetamide
2-(furyl)-3-(5-nitro-2-furyl)acrylamide
2-(2-furyl)-3-(5-nitrofuryl)acrylamide
nsc 44973
alpha-2-furyl-5-nitro-2-furanacrylamide
hsdb 4345
ccris 10
2-furanacrylamide, alpha-2-furyl-5-nitro-
2-(2-furyl)-3-(5-nitro-2-furyl)acrylic acid amide
C04622
(z)-2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide
CHEMBL259747
smr001527425
C19558
unii-054nr2135y
054nr2135y ,
furylfuramide [hsdb]
(z)-2-(2-furyl)-3-(5-nitro-2-furyl)prop-2-enamide
SCHEMBL106825
DTXSID9020033
Q3267971

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The result suggests that the acquired resistance to a toxic dose of furylfuramide is due to the acceleration of detoxication of the drug."( Development of resistance to hepatotoxic effect of furylfuramide by pretreatment with its subnecrotic doses and carbon tetrachloride.
Horiuchi, T; Ohtsubo, K; Saito, M, 1978
)
0.26

Dosage Studied

ExcerptRelevanceReference
" Moreover, RIP140 decreases the ED50 of the dose-response curve."( RIP 140 enhances nuclear receptor-dependent transcription in vivo in yeast.
Balaguer, P; Cavaillès, V; Joyeux, A; Nicolas, JC, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
acrylamidesAn enamide which is acrylamide or a derivative of acrylamide obtained by replacement of one or more of its hydrogens.
nitrofuran antibioticA member of the class of furans in which the furan ring is substituted by a nitro group and which also has significant antibiotic properties.
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
primary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with ammonia; formula RC(=O)NH2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID318681Anticarcinogenic activity in rat assessed as induction of tumors per day2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
QSAR modeling of the rodent carcinogenicity of nitrocompounds.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (168)

TimeframeStudies, This Drug (%)All Drugs %
pre-199058 (34.52)18.7374
1990's20 (11.90)18.2507
2000's25 (14.88)29.6817
2010's9 (5.36)24.3611
2020's56 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (2.37%)5.53%
Reviews9 (5.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other156 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]